Edwards Lifesciences Lifts 2026 Guidance to 9%–11% After 11% TAVR Growth
Edwards Lifesciences raised its full-year 2026 sales growth guidance to 9%–11% and adjusted EPS to $2.95–3.05 after reporting global TAVR growth of 11% and a slight gross margin dip to 78.2% due to currency and manufacturing costs. Leadership highlighted EARLY TAVR and seven-year PARTNER 3 data driving SAPIEN adoption and noted European share gains following a competitor’s exit.
1. Q1 Performance and Margin
Edwards reported global TAVR procedure growth of 11% in Q1 2026 and saw adjusted gross profit margin decline to 78.2% from 78.7% year-over-year due to currency headwinds and higher manufacturing expenses.
2. Guidance Raised for 2026
Management raised full-year 2026 sales growth guidance to 9%–11% and adjusted EPS outlook to $2.95–3.05, noting variability in quarterly growth rates based on timing of clinical and regulatory catalysts.
3. TAVR Momentum and Market Share
Strong long-term data from EARLY TAVR trials and seven-year PARTNER 3 results underpin renewed device adoption, while a competitor’s European exit contributed to market share gains with ongoing CMS NCD uncertainty.
4. Pipeline and New Products
The rollout of SAPIEN M3 is driving initial adoption in key trial centers, PASCAL and EVOQUE are fueling transcatheter mitral and tricuspid therapies growth, and SAPIEN X4 confirmatory trials are planned throughout 2026 for personalized valve sizing.